Fennec Pharmaceuticals Inc. Announces Annual Meeting of Shareholders on June 25, 2024

TL;DR

<b>Fennec Pharmaceuticals Inc. will hold its annual shareholder meeting on June 25, 2024, to review financial statements, elect directors, appoint auditors, and vote on executive compensation.</b>

AI Summary

FENNEC PHARMACEUTICALS INC. (FENC) filed a Proxy Statement (DEF 14A) with the SEC on May 13, 2024. Fennec Pharmaceuticals Inc. will hold its annual meeting of shareholders on June 25, 2024, at 10:00 a.m. EDT. The meeting will take place at Nasdaq Marketsite in New York and online via virtual shareholdermeeting.com/FENC2024. Shareholders will receive the audited consolidated financial statements for the year ended December 31, 2023. The agenda includes the election of five directors and the appointment of auditors for the year ending December 31, 2024. Shareholders will also vote on an advisory basis regarding the compensation of Named Executive Officers.

Why It Matters

For investors and stakeholders tracking FENNEC PHARMACEUTICALS INC., this filing contains several important signals. This meeting is a key opportunity for shareholders to directly influence the company's governance by electing directors and approving auditor appointments. The advisory vote on executive compensation allows shareholders to express their views on how the company is rewarding its top executives, potentially impacting future compensation structures.

Risk Assessment

Risk Level: low — FENNEC PHARMACEUTICALS INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting and does not contain new material financial or operational information that would indicate significant risk.

Analyst Insight

Shareholders should review the proxy materials to make informed decisions on director elections and executive compensation before the June 25, 2024 meeting.

Key Numbers

• 5 — Directors (Number of directors to be elected at the meeting.)
• 2024 — Fiscal Year End (The fiscal year for which auditors are being appointed.)

Key Players & Entities

• Fennec Pharmaceuticals Inc. (company) — Registrant and filer of the proxy statement.
• June 25, 2024 (date) — Date of the annual meeting of shareholders.
• Nasdaq Marketsite (company) — Location of the physical annual meeting.
• December 31, 2023 (date) — End of the fiscal year for which financial statements will be presented.

FAQ

Industry Context

Fennec Pharmaceuticals operates in the biotechnology sector, focusing on the development of pharmaceutical products.

Regulatory Implications

The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Examine the company's financial performance for the year ended December 31, 2023.
3. Understand the advisory vote on executive compensation and cast an informed vote.

Key Dates

• 2024-06-25: Annual Meeting of Shareholders — Shareholders will vote on key corporate matters including director elections and executive compensation.

Year-Over-Year Comparison

This is a routine DEF 14A filing for the annual shareholder meeting and does not provide comparative data from a previous filing within this document.

Filing Documents

• tmb-20240625xdef14a.htm (DEF 14A) — 991KB
• tmb-20240625xdef14a_a003.jpg (GRAPHIC) — 73KB
• tmb-20240625xdef14a_bg001.jpg (GRAPHIC) — 120KB
• tmb-20240625xdef14a_bg002.jpg (GRAPHIC) — 120KB
• 0001558370-24-007979.txt (&nbsp;) — 1424KB

From the Filing

DEF 14A 1 tmb-20240625xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 FENNEC PHARMACEUTICALS INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. FENNEC PHARMACEUTICALS INC. NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 25, 2024 NOTICE IS HEREBY GIVEN that the annual meeting (the " Meeting ") of the holders of common shares (" Common Shares ") in the capital of Fennec Pharmaceuticals Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, 27709 (" Fennec " or the " Corporation ") will be held on June 25, 2024 at 10:00 a.m. EDT at Nasdaq Marketsite in the Apollo Room, 4 Times Square, Nasdaq, New York, NY 10036, USA and online by visiting www.virtualshareholdermeeting.com/FENC2024, where you will be able to listen to the meeting live, submit questions, and vote, for the following purposes: 1. to receive the audited consolidated financial statements of the Corporation for the year ended December 31, 2023, together with the report of the auditors thereon; 2. to elect the five directors named in the Management Proxy Circular; 3. to appoint auditors for the year ending December 31, 2024, and to authorize the directors of the Corporation to fix the auditors' remuneration; 4. to vote, on an advisory (non-binding) basis, on the compensation of our Named Executive Officers; and 5. to transact such further or other business as may properly come before the Meeting or any adjournment thereof. Shareholders attending the Meeting online may register and log into the live audio webcast platform beginning at 9:45 a.m. EDT on the Meeting date. We would appreciate your early registration so that the Meeting may start promptly at 10:00 a.m. EDT on the Meeting date. The board of directors of Fennec has fixed 5:00 p.m. EDT on April 29, 2024 (the " Record Date "), as the record date for determining the holders of record of Common Shares who are entitled to receive notice of the Meeting and to attend and vote at the Meeting and any adjournment or postponement thereof. Fennec is holding a "hybrid" meeting that includes both an in-person and virtual online component. Only registered shareholders or proxyholders for registered shareholders will be permitted to attend the Meeting. In particular, Shareholders may attend the Meeting in person, online by visiting www.virtualshareholdermeeting.com/FENC2024, or may be represented at the Meeting by proxy. Proxies to be used at the Meeting must be received no later than 11:59 p.m. (EDT) on June 24, 2024 and, if the Meeting is postponed or adjourned, no later than 48 hours (excluding weekends and statutory holidays) preceding the reconvened Meeting. Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be held on June 25, 2024: This Notice, Management Proxy Circular and the Corporation's Annual Report on Form 10-K are available to you on the Internet at www.proxyvote.com. We encourage you to access and review all of the important information contained in these materials before voting. DATED at Research Triangle Park, North Carolina this 29 th day of April, 2024. By Order of the Board of Directors of Fennec Pharmaceuticals Inc. /s/ Khalid Islam Dr. Khalid Islam Chairman of the Board Page 1 FENNEC PHARMACEUTICALS INC. MANAGEMENT PROXY CIRCULAR Unless otherwise stated, information contained in this management proxy circular (the " Circular ") is given as of April 29, 2024 . Except as otherwise indicated, all amounts are expressed in United States dollars. The Meeting This Circular is furnished in connection with the solicitation of proxies by management of Fennec Pharmaceuticals Inc., 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, 27709 (" Fennec " or the " Corporation ") for use at the annual meeting (the " Meeting ") of the shareholders of Fennec to be held on June 25, 2024 at 10:00 a.m. EDT at Nasdaq Marketsite in the Apollo Room, 4 Times Square, 27th Floor, Nasdaq, New York, NY 10036, USA and online by visiting www.virtualshareholdermeeting.com/FENC2024, and at any adjournment thereof, for the purposes set forth in the accompanying notice of annual meeting (the " Notice of Meeting "). The Meeting will be held in a

View Full Filing

View this DEF 14A filing on SEC EDGAR